Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation

NCT07904507 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT07904507 Not yet recruiting Phase 4 266 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07904507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, Phase 4, 266 participants (estimated). Lead sponsor University Hospital, Basel, Switzerland; Switzerland. Primary measure: Atrial-Fibrillation-related Quality of Life.

How it compares

345 similar trials: same condition (Atrial Fibrillation) and phase

Enrollment

This trial
266
Middle half
74 to 400
Median
178
Trials with a value
345

Months from start to completion

This trial
35
Middle half
24 to 58.7
Median
36
Trials with a value
340

Sites

This trial
1
Middle half
1 to 4
Median
1
Trials with a value
315
Posted results or a linked paper 57% 197 of 345 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation
Official title
BRACE-AFib: Beta-blocker Replacement and Calcium Channel Blockers Evaluation in Atrial Fibrillation
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 4
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
October 31, 2029
Enrollment
266 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Arrhythmias, Cardiac, Atrial Fibrillation

Registry terms: atrial fibrillation (af)

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
Switzerland
Lead sponsor
University Hospital, Basel, Switzerland

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Diltiazem Experimental Experimental intervention
Show registry wording

133 patients are randomized to the experimental intervention and treated with the non-dihydropyridine calcium channel blocker (NDCC) Diltiazem.

Bisoprolol Active comparator Control Intervention
Show registry wording

133 patients are randomized to the control arm and treated with the beta-blocker Bisoprolol.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Atrial-Fibrillation-related Quality of Life From baseline to 3 months
Show registry wording

Change in Atrial-Fibrillation-related Quality of Life between Non-dihydropyridine calcium channel blockers (NDCC) versus continuation of beta-blockers (BB) from baseline to 3 months in patients with Atrial-Fibrillation.

The primary outcome uses the AFEQT questionnaire:

The AFEQT 20-item questionnaire is a validated, AF-specific QoL tool. It assesses 4 domains: symptoms, daily activities, treatment concerns, and treatment satisfaction. The overall AFEQT score is calculated using the first 3 domains and ranges from 0 = worst to 100 = best QoL. Additionally, for each domain of interest, there is a corresponding subscale score: symptoms, daily activities, treatment concerns, and treatment satisfaction subscale scores. Each subscale ranges from 0 = worst to 100 = best QoL and is scored separately. The AFEQT questionnaire will be done at baseline before the intake of the first study drug and after three months of intervention.

Lead sponsor's other trials

University Hospital, Basel, Switzerland, most recent start first.

Similar trials

Same condition (Atrial Fibrillation) and phase, most recent start first.